An updated patent review of calpain inhibitors (2012 – 2014)

Bibliography

• Sorimachi H, Hata S, Ono Y. Impact of genetic insights into calpain biology. J Biochem 2011;150:23-37
   PubMed Web of Science ®Google Scholar
• Sorimachi H, Hata S, Ono Y. Expanding members and roles of the calpain superfamily and their genetically modified animals. Exp Anim 2010;59:549-66
   PubMed Web of Science ®Google Scholar
• Ohno S, Emori Y, Imajoh S, et al. Evolutionary origin of a calcium-dependent protease by fusion of genes for a thiol protease and a calcium-binding protein? Nature 1984;312:566-70
   PubMed Web of Science ®Google Scholar
• Hanna RA, Campbell RL, Davies PL. Calcium-bound structure of calpain and its mechanism of inhibition by calpastatin. Nature 2008;456:409-12
   PubMed Web of Science ®Google Scholar
• Qian J, Cuerrier D, Davies PL, et al. Cocrystal structures of primed side-extending alpha-ketoamide inhibitors reveal novel calpain-inhibitor aromatic interactions. J Med Chem 2008;51:5264-70
   PubMed Web of Science ®Google Scholar
• Covault J, Liu QY, el-Deeb S. Calcium-activated proteolysis of intracellular domains in the cell adhesion molecules NCAM and N-cadherin. Brain Res Mol Brain Res 1991;11:11-16
   PubMedGoogle Scholar
• Davies PJ, Wallach D, Willingham MC, et al. Filamin-actin interaction. Dissociation of binding from gelation by Ca2+-activated proteolysis. J Biol Chem 1978;253:4036-42
   PubMed Web of Science ®Google Scholar
• Yoshida K, Inui M, Harada K, et al. Reperfusion of rat heart after brief ischemia induces proteolysis of calspectin (nonerythroid spectrin or fodrin) by calpain. Circ Res 1995;77:603-10
   PubMed Web of Science ®Google Scholar
• Löfvenberg L, Backman L. Calpain-induced proteolysis of beta-spectrins. FEBS Lett 1999;443:89-92
   PubMed Web of Science ®Google Scholar
• Hemmings L, Rees DJ, Ohanian V, et al. Talin contains three actin-binding sites each of which is adjacent to a vinculin-binding site. J Cell Sci 1996;109(Pt 11):2715-26
   PubMedGoogle Scholar
• Nelson WJ, Traub P. Proteolysis of vimentin and desmin by the Ca2+-activated proteinase specific for these intermediate filaments. Mol Cell Biol 1983;3:1146-56
   PubMed Web of Science ®Google Scholar
• Ito M, Tanaka T, Nunoki K, et al. The Ca2+-activated protease (calpain) modulates Ca2+/calmodulin dependent activity of smooth muscle myosin light chain kinase. Biochem Biophys Res Commun 1987;145:1321-8
   PubMed Web of Science ®Google Scholar
• Kishimoto A, Mikawa K, Hashimoto K, et al. Limited proteolysis of protein kinase C subspecies by calcium-dependent neutral protease (calpain). J Biol Chem 1989;264:4088-92
   PubMed Web of Science ®Google Scholar
• Frangioni JV, Oda A, Smith M, et al. Calpain-catalyzed cleavage and subcellular relocation of protein phosphotyrosine phosphatase 1B (PTP-1B) in human platelets. EMBO J 1993;12:4843-56
   PubMed Web of Science ®Google Scholar
• Pariat M, Salvat C, Bébien M, et al. The sensitivity of c-Jun and c-Fos proteins to calpains depends on conformational determinants of the monomers and not on formation of dimers. Biochem J 2000;345(Pt 1):129-38
   PubMedGoogle Scholar
• Gonen H, Shkedy D, Barnoy S, et al. On the involvement of calpains in the degradation of the tumor suppressor protein p53. FEBS Lett 1997;406:17-22
   PubMed Web of Science ®Google Scholar
• Crawford C. Protein and peptide inhibitors of calpain. In: Mellgren RL, Murachi T, editors. Intracellular calcium-dependent proteolysis. CRC, Boca Raton, FL; 1990. p. 75-89
   Google Scholar
• Arthur JS, Elce JS, Hegadorn C, et al. Disruption of the murine calpain small subunit gene, Capn4: calpain is essential for embryonic development but not for cell growth and division. Mol Cell Biol 2000;20:4474-81
   PubMed Web of Science ®Google Scholar
• Fox JEB, Saido TC. Calpain in signal transduction. In: Wang KKK, Yuen P-W, editors. Calpain: pharmacology and toxicology of calcium-dependent protease. Taylor and Francis, Philadelphia, PA; 1999. p. 103-26
   Google Scholar
• Kidd VJ, Lahti JM, Teitz T. Proteolytic regulation of apoptosis. Semin Cell Dev Biol 2000;11:191-210
   PubMed Web of Science ®Google Scholar
• Watanabe N, Vande Woude GF, Ikawa Y, Sagata N. Specific proteolysis of the c-mos proto-oncogene product by calpain on fertilization of Xenopus eggs. Nature 1989;342:505-11
   PubMed Web of Science ®Google Scholar
• Lynch G. Memory and the brain: unexpected chemistries and a new pharmacology. Neurobiol Learn Mem 1998;70:82-100
   PubMed Web of Science ®Google Scholar
• Saido TC, Sorimachi H, Suzuki K. Calpain: new perspectives in molecular diversity and physiological-pathological involvement. FASEB J 1994;8:814-22
   PubMed Web of Science ®Google Scholar
• Richard I, Broux O, Allamand V, et al. Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A. Cell 1995;81:27-40
   PubMed Web of Science ®Google Scholar
• Saez ME, Ramirez-Lorca R, Moron FJ, Ruiz A. The therapeutic potential of the calpain family: new aspects. Drug Discov Today 2006;11:917-23
   PubMed Web of Science ®Google Scholar
• Donkor IO. Calpain inhibitors: a survey of compounds reported in the patent and scientific literature. Expert Opin Ther Pat 2011;21:601-36
   PubMed Web of Science ®Google Scholar
• Pietsch M, Chua KC, Abell AD. Calpains: attractive targets for the development of synthetic inhibitors. Curr Top Med Chem 2010;10:270-93
   PubMed Web of Science ®Google Scholar
• Universidad De Alcala. Derivatives of 5-azolones as calpain inhibitors. WO014314; 2013
   Google Scholar
• Abbott GmbH & Co. Carboxamide compounds and their use as calpain inhibitors. US0286146; 2010
   Google Scholar
• Abbott GmbH & Co. Carboxamide compounds and their use as calpain inhibitors. US7728012; 2010
   Google Scholar
• Abbott Laboratories. Carboxamide compounds and their use as calpain inhibitors. US8283363; 2012
   Google Scholar
• AbbVie, Inc. Carboxamide compounds and their use as calpain inhibitors V. WO149800; 2013
   Google Scholar
• Baek KH, Karki R, Lee E-S, et al. Synthesis and investigation of dihydroxychalcones as calpain and cathepsin inhibitors. Bioorg Chem 2013;51:24-30
   PubMed Web of Science ®Google Scholar
• Wang KKW, Nath R, Posner A, et al. An alpha-mercaptoacrylic acid derivative is a selective nonpeptide cell-permeable calpain inhibitor and is neuroprotective. Proc Nat Acad Sci USA 1996;93:6687-92
   PubMed Web of Science ®Google Scholar
• Adams SE, Parr C, Miller DJ, et al. Potent inhibition of Ca2+-dependent activation of calpain-1 by novel mercaptoacrylates. MedChemComm 2012;3:566-70
   Web of Science ®Google Scholar
• Adams SE, Rizkallah PJ, Miller DJ, et al. The structural basis of differential inhibition of human calpain by indole and phenyl α-mercaptoacrylic acids. J Struct Biol 2014;187:236-41
   PubMed Web of Science ®Google Scholar
• Dumartin L, Whiteman HJ, Weeks ME, et al. AGR2 is a novel surface antigen that promotes the dissemination of pancreatic cancer cells through regulation of cathepsins B and D. Cancer Res 2011;71:7091-102
   PubMed Web of Science ®Google Scholar
• Berdowska I. Cysteine proteases as disease markers. Clin Chim Acta 2004;342:41-69
   PubMed Web of Science ®Google Scholar
• Greenbaum DC. Novel α-helical peptidomimetic inhibitors and methods using same. WO163567; 2013
   Google Scholar
• Jo H, Meinhardt N, Wu Y, et al. Development of α-helical calpain probes by mimicking a natural protein-protein interaction. J Am Chem Soc 2012;134:17704-13
   PubMed Web of Science ®Google Scholar
• Henchey LK, Jochim AL, Arora PS. Contemporary strategies for the stabilization of peptides in the alpha-helical conformation. Curr Opin Chem Biol 2008;12:692-7
   PubMed Web of Science ®Google Scholar
• Donkor IO. A survey of calpain inhibitors. Curr Med Chem 2000;7:1171-88
   PubMed Web of Science ®Google Scholar
• Satoyashi E. Therapeutic trials on progressive muscular dystrophy. Intern Med 1992;31:841-6
   PubMed Web of Science ®Google Scholar
• Towatari T, Nikawa T, Murata M, et al. Novel epoxysuccinyl peptides. A selective inhibitor of cathepsin B, in vivo. FEBS Lett 1991;280:311-15
   PubMed Web of Science ®Google Scholar
• Hook G, Hook VY, Kindy M. Cysteine protease inhibitors reduce brain beta-amyloid and beta-secretase activity in vivo and are potential Alzheimer’s disease therapeutics. Biol Chem 2007;388:979-83
   PubMed Web of Science ®Google Scholar
• Schiefer IT, Tapadar S, Litosh V, et al. Design, synthesis, and optimization of novel epoxide incorporating peptidomimetics as selective calpain inhibitors. J Med Chem 2013;56:6054-68
   PubMed Web of Science ®Google Scholar
• Arancio O, Fa M, Schiefer IT, Thatcher GR. Novel cysteine protease inhibitors and uses thereof. WO116663; 2013
   Google Scholar
• Suzuki K, Hayashi H, Hayashi T, Iwai K. Amino acid sequence around the active site cysteine residue of calcium-activated neutral protease (CANP). FEBS Lett 1983;152:67-70
   PubMed Web of Science ®Google Scholar
• Cuerrier D, Moldoveanu T, Campbell RL, et al. Development of calpain-specific inactivators by screening of positional scanning epoxide libraries. J Biol Chem 2007;282:9600-11
   PubMed Web of Science ®Google Scholar
• Banoczi Z, Tantos A, Farkas A, et al. New mcalpain substrate-based azapeptide inhibitors. J Pept Sci 2013;19:370-6
   PubMed Web of Science ®Google Scholar
• Tompa P, Buzder-Lantos P, Tantos A, et al. On the sequential determinants of calpain cleavage. J Biol Chem 2004;279:20775-85
   PubMed Web of Science ®Google Scholar
• Dokus LE, Menyhard DK, Tantos A, et al. Probing of primed and unprimed sites of calpains: design, synthesis and evaluation of epoxysuccinyl-peptide derivatives as selective inhibitors. Eur J Med Chem 2014;82:274-80
   PubMed Web of Science ®Google Scholar
• Yamashima T, Kohda Y, Tsuchiya K, et al. Implication of cysteine proteases calpain, cathepsin and caspase in ischemic neuronal deat. Prog Neurobiol 2000;62:273-95
   PubMed Web of Science ®Google Scholar
• Asahi M, Asahi K, Jung JC, et al. Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94. J Cereb Blood Flow Metab 2000;20:1681-9
   PubMed Web of Science ®Google Scholar
• Kupina NC, Nath R, Bernath EE, et al. The novel calpain inhibitor SJA6017 improves functional outcome after delayed administration in a mouse model of diffuse brain injury. J Neurotrauma 2001;18:1229-40
   PubMed Web of Science ®Google Scholar
• Kawamura M, Nakajima W, Ishida A, et al. Calpain inhibitor MDL 28170 protects hypoxic-ischemic brain injury in neonatal rats by inhibition of both apoptosis and necrosis. Brain Res 2005;1037(1-2):59-69
   PubMed Web of Science ®Google Scholar
• Wang CH, Chen YJ, Lee TH, et al. Protective effect of MDL28170 against thioacetamide-induced acute liver failure in mice. J Biomed Sci 2004;11:571-8
   PubMed Web of Science ®Google Scholar
• Canbay A, Feldstein A, Baskin-Bey E, et al. The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse. J Pharmacol Exp Ther 2004;308:1191-6
   PubMed Web of Science ®Google Scholar
• Banyan Biomarkers. Dipeptide calpain inhibitors. WO021788; 2012
   Google Scholar
• Kang CW, Sun Y, Valle JRD. Substituted imidazo[1,2-a]pyridines as beta-strand Peptidomimetics. Org Lett 2012;14:6161-5
   Web of Science ®Google Scholar
• Chatterjee J, Laufer B, Kessler H. Synthesis of N-methylated cyclic peptides. Nat Protoc 2012;7:432-44
   PubMed Web of Science ®Google Scholar
• Jones SA, Neilsen PM, Siew L, et al. A Template-based approach to inhibitors of calpain 2, 20S proteasome, and HIV-1 protease. ChemMedChem 2013;8:1918-21
   PubMed Web of Science ®Google Scholar
• Pehere AD, Abell AD. New β-strand templates constrained by Huisgen cycloaddition. Org Lett 2012;14:2012
   Web of Science ®Google Scholar
• Pehere AD, Pietsch M, Gutschow M, et al. Synthesis and extended activity of triazole-containing macrocyclic protease inhibitors. Chemistry 2013;19:7975-81
   PubMed Web of Science ®Google Scholar
• Chen H, Jiao W, Jones MA, et al. New tripeptide-based macrocyclic calpain inhibitors formed by N-alkylation of histidine. Chem Biodivers 2012;9:2473-84
   PubMed Web of Science ®Google Scholar
• Abell AD, Chua K. Macrocyclic compounds and uses thereof. WO075146; 2014
   Google Scholar
• Nakazawa M. Effects of calcium ion, calpains, and calcium channel blockers on retinitis pigmentosa. J Ophthalmol 2011;2011:292040
   PubMed Web of Science ®Google Scholar
• Mizukoshi S, Nakazawa M, Sato K, et al. Activation of mitochondrial calpain and release of apoptosis-inducing factor from mitochondria in RCS rat retinal degeneration. Exp Eye Res 2010;91:353-61
   PubMed Web of Science ®Google Scholar
• Suzuki R, Oka T, Tamada Y, et al. Degeneration and dysfunction of retinal neurons in acute ocular hypertensive rats: involvement of calpains. J Ocul Pharmacol Ther 2014;30:419-28
   PubMed Web of Science ®Google Scholar
• Hoffmann DB, Williams SK, Bojceyski J, et al. Calcium influx and calpain activation mediate preclinical retinal neurodegeneration in autoimmune optic neuritis. J Neuropathol Exp Neurol 2013;72:745-57
   PubMed Web of Science ®Google Scholar
• Ishiguro S, Ozaki H, Nakazawa M, Yamashita T. Mitochondrial calpain-inhibiting peptides and pharmaceuticals containing the peptides for prevention and treatment of retinal call degradation. JP047164; 2014
   Google Scholar
• Ozaki T, Nakazawa M, Yamashita T, et al. Intravitreal injection or topical eye-drop application of a μ-calpain C2L domain peptide protects against photoreceptor cell death in Royal College of Surgeons’ rats, a model of retinitis pigmentosa. Biochim Biophys Acta 2012;1822:1783-95
   PubMed Web of Science ®Google Scholar
• David LD, Varnum MD, Lampi KJ, Shearer TR. Calpain II in human lens. Invest Ophthalmol Vis Sci 1989;30:269-75
   PubMed Web of Science ®Google Scholar
• Robertson LJG, Morton JD, Yamaguchi M, et al. Calpain may contribute to hereditary cataract formation in sheep. Invest Ophthalmol Vis Sci 2005;46:4634-40
   PubMed Web of Science ®Google Scholar
• Sanderson J, Marcantonio JM, Duncan G. A human lens model of cortical cataract: Ca2+-induced protein loss, vimentin cleavage and opacification. Invest Ophthalmol Vis Sci 2000;41:2255-61
   PubMed Web of Science ®Google Scholar
• Abell AD, Coxon JM, Jones MA, et al. Molecular modeling, synthesis and biological evaluation of macrocyclic calpain inhibitors. Angew Chem Int Ed Engl 2009;48:1455-8
   PubMed Web of Science ®Google Scholar
• Morton JD, Lee HYY, McDermott JD, et al. A macrocyclic calpain inhibitor slows the development of inherited cortical cataracts in a sheep model. Invest Ophthalmol Vis Sci 2013;54:389-95
   PubMed Web of Science ®Google Scholar
• Conway KA, Baxter EW, Felsenstein KM, Reits AB. Emerging beta-amyloid therapies for the treatment of Alzheimer’s disease. Curr Pharm Des 2003;9:427-47
   PubMed Web of Science ®Google Scholar
• Selkoe DJ. The molecular pathology of Alzheimer’s disease. Neuron 1991;6:487-98
   PubMed Web of Science ®Google Scholar
• Saido TC, Shibata M, Takenawa T, et al. Positive regulation of mu-calpain action by polyphosphoinositides. J Biol Chem 1992;267:24585-90
   PubMed Web of Science ®Google Scholar
• Salamino F, De Tullio R, Mengotti P, et al. Site-directed activation of calpain is promoted by a membrane-associated natural activator protein. Biochem J 1993;290:191-7
   PubMed Web of Science ®Google Scholar
• Saito K, Elce JS, Hamos JE, Nixon RA. Widespread activation of calcium activated neutral proteinase (calpain) in the brain in Alzheimer disease: a potential molecular basis for neuronal degeneration. Proc Natl Acad Sci USA 1993;90:2628-32
   PubMed Web of Science ®Google Scholar
• Lee MS, Kwon YT, Li M, et al. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 2000;405:360-4
   PubMed Web of Science ®Google Scholar
• Hashiguchi M, Saito T, Hisanaga S, Hashiguchi T. Truncation of CDK5 activator p35 induces intensive phosphorylation of Ser202/Thr205 of human tau. J Biol Chem 2002;277:44525-30
   PubMed Web of Science ®Google Scholar
• Cruz JC, Tseng HC, Goldman JA, et al. Aberrant CDK5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron 2003;30:471-83
   Google Scholar
• Noble W, Olm V, Takata KK, et al. CDK5 is a key factor in tau aggregation and tangle formation in vivo. Neuron 2003;38:555-65
   PubMed Web of Science ®Google Scholar
• Kwon Y, Lee E. Undecylenate and conjugated linoleate for the treatment of neurological disorders. WO026662; 2012
   Google Scholar
• Lee E, Eom J-E, Kim H-L, et al. Neuroprotective effect of undecylenic acid extracted from Ricinus communis L. through inhibition of mu-calpain. Eur J Pharm Sci 2012;46:17-25
   PubMed Web of Science ®Google Scholar
• Norwood F, Harling C, Chinnery P, et al. Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population. Brain 2009;132:3175-86
   PubMed Web of Science ®Google Scholar
• Richard I, Charton K. Calpain-3 inhibitors for treating muscular dystrophies and cardiomyopathies. US0171172; 2013
   Google Scholar
• Baghdiguian S, Martin M, Richard I, et al. Calpain 3 deficiency is associated with myonuclear apoptosis and profound perturbation of the IkappaB alpha/NF-kappaB pathway in limb-girdle muscular dystrophy type 2A. Nat Med 1999;5:503-11
   PubMed Web of Science ®Google Scholar
• Richard I, Routdaut C, Marchand S, et al. Loss of calpain 3 proteolytic activity leads to muscular dystrophy and to apoptosis-associated IkappaBalpha/nuclear factor kappaB pathway perturbation in mice. J Cell Biol 2000;151:1583-90
   PubMed Web of Science ®Google Scholar
• Nemirovskaya TL, Lomonosova YN. Method for preventing and reducing destruction of skeletal muscle proteins in atrophy caused by hypokinesia and/or gravisensing. RU2517576 C1 0527; 2014
   Google Scholar
• Wieschhaus A, Khan A, Zaidi A, et al. Calpain-1 knockout reveals broad effects on erythrocyte deformability and physiology. Biochem J 2012;448:141-52
   PubMed Web of Science ®Google Scholar
• Chishti A. Identification and use of protease inhibitors to treat or prevent sickle disease. WO067415; 2013
   Google Scholar
• Peyron J-F, Lagadec P. Methods for monitoring the response to treatment and for treating colorectal cancer. WO110425; 2012
   Google Scholar
• INSERM. Methods and pharmaceutical compositions for prevention of aging-related lesions. WO096087; 2014
   Google Scholar
• Inserte J, Hernando V, Garcia-Dorado D. Contribution of calpains to myocardial ischaemia/reperfusion injury. Cardiovasc Res 2012;96:23-31
   PubMed Web of Science ®Google Scholar
• Inserte J, Garcia-Dorado D, Ruiz-Meana M, et al. Ischemic preconditioning attenuates calpain-mediated degradation of structural proteins through a protein kinase A-dependent mechanism. Cardiovasc Res 2004;64:105-14
   PubMed Web of Science ®Google Scholar
• Inserte J, Garcia-Dorado D, Hernando V, et al. Ischemic preconditioning prevents calpain-mediated impairment of Na+/K+-ATPase activity during early reperfusion. Cardiovasc Res 2006;70:364-73
   PubMed Web of Science ®Google Scholar